BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 28383633)

  • 1. Randomized phase III trial of S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer: SALTO study by the Dutch Colorectal Cancer Group.
    Kwakman JJM; Simkens LHJ; van Rooijen JM; van de Wouw AJ; Ten Tije AJ; Creemers GJM; Hendriks MP; Los M; van Alphen RJ; Polée MB; Muller EW; van der Velden AMT; van Voorthuizen T; Koopman M; Mol L; van Werkhoven E; Punt CJA
    Ann Oncol; 2017 Jun; 28(6):1288-1293. PubMed ID: 28383633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Capecitabine versus S-1 as adjuvant chemotherapy for patients with stage III colorectal cancer (JCOG0910): an open-label, non-inferiority, randomised, phase 3, multicentre trial.
    Hamaguchi T; Shimada Y; Mizusawa J; Kinugasa Y; Kanemitsu Y; Ohue M; Fujii S; Takiguchi N; Yatsuoka T; Takii Y; Ojima H; Masuko H; Kubo Y; Mishima H; Yamaguchi T; Bando H; Sato T; Kato T; Nakamura K; Fukuda H; Moriya Y
    Lancet Gastroenterol Hepatol; 2018 Jan; 3(1):47-56. PubMed ID: 29079411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of efficacy and safety of S-1 and capecitabine in patients with metastatic colorectal carcinoma: A systematic review and meta-analysis.
    Chen J; Wang J; Xu T
    Medicine (Baltimore); 2019 Jul; 98(30):e16667. PubMed ID: 31348323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer: A Randomized Clinical Trial.
    Mettu NB; Ou FS; Zemla TJ; Halfdanarson TR; Lenz HJ; Breakstone RA; Boland PM; Crysler OV; Wu C; Nixon AB; Bolch E; Niedzwiecki D; Elsing A; Hurwitz HI; Fakih MG; Bekaii-Saab T
    JAMA Netw Open; 2022 Feb; 5(2):e2149040. PubMed ID: 35179586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial.
    Yamada Y; Denda T; Gamoh M; Iwanaga I; Yuki S; Shimodaira H; Nakamura M; Yamaguchi T; Ohori H; Kobayashi K; Tsuda M; Kobayashi Y; Miyamoto Y; Kotake M; Shimada K; Sato A; Morita S; Takahashi S; Komatsu Y; Ishioka C
    Ann Oncol; 2018 Mar; 29(3):624-631. PubMed ID: 29293874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial.
    Hong YS; Park YS; Lim HY; Lee J; Kim TW; Kim KP; Kim SY; Baek JY; Kim JH; Lee KW; Chung IJ; Cho SH; Lee KH; Shin SJ; Kang HJ; Shin DB; Jo SJ; Lee JW
    Lancet Oncol; 2012 Nov; 13(11):1125-32. PubMed ID: 23062232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized study of orally administered fluorinated pyrimidines (capecitabine versus S-1) in women with metastatic or recurrent breast cancer: Japan Breast Cancer Research Network 05 Trial.
    Yamamoto D; Iwase S; Tsubota Y; Ariyoshi K; Kawaguchi T; Miyaji T; Sueoka N; Yamamoto C; Teramoto S; Odagiri H; Kitamura K; Nagumo Y; Yamaguchi T
    Cancer Chemother Pharmacol; 2015 Jun; 75(6):1183-9. PubMed ID: 25862350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of oral administration of cystine and theanine in colorectal cancer patients undergoing capecitabine-based adjuvant chemotherapy after surgery: a multi-institutional, randomized, double-blinded, placebo-controlled, phase II trial (JORTC-CAM03).
    Hamaguchi R; Tsuchiya T; Miyata G; Sato T; Takahashi K; Miura K; Oshio H; Ohori H; Ariyoshi K; Oyamada S; Iwase S
    Support Care Cancer; 2020 Aug; 28(8):3649-3657. PubMed ID: 31811480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9.
    Winther SB; Österlund P; Berglund Å; Glimelius B; Qvortrup C; Sorbye H; Pfeiffer P;
    BMC Cancer; 2017 Aug; 17(1):548. PubMed ID: 28814275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Term Safety Data on S-1 Administered After Previous Intolerance to Capecitabine-Containing Systemic Treatment for Metastatic Colorectal Cancer.
    Punt CJA; Kwakman JJM; Mol L;
    Clin Colorectal Cancer; 2022 Sep; 21(3):229-235. PubMed ID: 35341693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of Hand-Foot Syndrome and Pyridoxine for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Randomized Clinical Trial.
    Yap YS; Kwok LL; Syn N; Chay WY; Chia JWK; Tham CK; Wong NS; Lo SK; Dent RA; Tan S; Mok ZY; Koh KX; Toh HC; Koo WH; Loh M; Ng RCH; Choo SP; Soong RCT
    JAMA Oncol; 2017 Nov; 3(11):1538-1545. PubMed ID: 28715540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Experience with S-1 in older Caucasian patients with metastatic colorectal cancer (mCRC): Findings from an observational chart review.
    Winther SB; Zubcevic K; Qvortrup C; Vestermark LW; Jensen HA; Krogh M; Sorbye H; Pfeiffer P;
    Acta Oncol; 2016 Jul; 55(7):881-5. PubMed ID: 27181284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Updated Survival Analysis of the Randomized Phase III Trial of S-1 Versus Capecitabine in the First-Line Treatment of Metastatic Colorectal Cancer by the Dutch Colorectal Cancer Group.
    Kwakman JJM; van Werkhoven E; Simkens LHJ; van Rooijen JM; van de Wouw YAJ; Tije AJT; Creemers GM; Hendriks MP; Los M; van Alphen RJ; Polée MB; Muller EW; van der Velden AMT; van Voorthuizen T; Koopman M; Mol L; Punt CJA
    Clin Colorectal Cancer; 2019 Jun; 18(2):e229-e230. PubMed ID: 30782413
    [No Abstract]   [Full Text] [Related]  

  • 14. Phase II study of oral S-1 with irinotecan and bevacizumab (SIRB) as first-line therapy for patients with metastatic colorectal cancer.
    Yamada Y; Yamaguchi T; Matsumoto H; Ichikawa Y; Goto A; Kato K; Hamaguchi T; Shimada Y
    Invest New Drugs; 2012 Aug; 30(4):1690-6. PubMed ID: 21894500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of oral administration of cystine and theanine in patients with colorectal cancer undergoing capecitabine-based adjuvant chemotherapy after surgery: study protocol for a multi-institutional, randomised, double-blinded, placebo-controlled, phase II trial.
    Hamaguchi R; Tsuchiya T; Miyata G; Sato T; Takahashi K; Ariyoshi K; Oyamada S; Iwase S
    BMJ Open; 2018 Jul; 8(7):e021442. PubMed ID: 30030317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized Phase II Trial of CapOX plus Bevacizumab and CapIRI plus Bevacizumab as First-Line Treatment for Japanese Patients with Metastatic Colorectal Cancer (CCOG-1201 Study).
    Nakayama G; Mitsuma A; Sunagawa Y; Ishigure K; Yokoyama H; Matsui T; Nakayama H; Nakata K; Ishiyama A; Asada T; Umeda S; Ezaka K; Hattori N; Takami H; Kobayashi D; Tanaka C; Kanda M; Yamada S; Koike M; Fujiwara M; Fujii T; Murotani K; Ando Y; Kodera Y
    Oncologist; 2018 Aug; 23(8):919-927. PubMed ID: 30049885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial.
    Kim ST; Hong YS; Lim HY; Lee J; Kim TW; Kim KP; Kim SY; Baek JY; Kim JH; Lee KW; Chung IJ; Cho SH; Lee KH; Shin SJ; Kang HJ; Shin DB; Lee JW; Jo SJ; Park YS
    BMC Cancer; 2014 Nov; 14():883. PubMed ID: 25424120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.
    Hegewisch-Becker S; Graeven U; Lerchenmüller CA; Killing B; Depenbusch R; Steffens CC; Al-Batran SE; Lange T; Dietrich G; Stoehlmacher J; Tannapfel A; Reinacher-Schick A; Quidde J; Trarbach T; Hinke A; Schmoll HJ; Arnold D
    Lancet Oncol; 2015 Oct; 16(13):1355-69. PubMed ID: 26361971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. S-1 plus Raltitrexed for Refractory Metastatic Colorectal Cancer: A Phase II Trial.
    Chen Y; Wu J; Cheng K; Li ZP; Luo DY; Qiu M; Gou HF; Yi C; Li Q; Wang X; Yang Y; Cao D; Shen YL; Bi F; Liu JY
    Oncologist; 2019 May; 24(5):591-e165. PubMed ID: 30651398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II study of capecitabine, irinotecan, and bevacizumab in patients with previously untreated metastatic colorectal cancer.
    Renouf DJ; Welch S; Moore MJ; Krzyzanowska MK; Knox J; Feld R; Liu G; MacKay H; Petronis J; Wang L; Chen E
    Cancer Chemother Pharmacol; 2012 May; 69(5):1339-44. PubMed ID: 22349811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.